Latest From Biotech Now

BIO CEO Company Snapshot: Tetraphase Pharmaceuticals

tetraphase

The BIO CEO & Investor Conference is now just a week away, and buzz for the event has never been greater. Tomorrow, Inside BIO is hosting its first ever twitter chat to discuss the annual buyside survey, which has been getting great responses from the investor community. Presentation spots are still sold out as well, and we’re continuing to highlight those companies slated to present. One such company is Tetraphase Pharmaceuticals, who went public this Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Life Science Leader on TransCelerate’s Efforts to Modernize Drug Development

TransCelerate Dalvir Gill

Life Science Leader’s Rob Wright has a great profile on TransCelerate BioPharma and their efforts to modernize the drug development and clinical trial landscape. TransCelerate is a nonprofit organization made up of 18 innovate biopharmaceutical companies dedicated to collaborating across the industry to find ways to simplify and accelerate the discovery of new medicines. As the article notes, the challenge involved is enormous: With combined annual revenues in excess of $300 billion and nearly 800,000 employees Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

2013 Novel Drug Approvals

Therapeutic-Indications-with-Novel-Drug-Approvals-in-2013-115x76

The FDA approved 24 novel drugs last year by our count, in line with average approvals for the last ten years but down from the decade-high approvals seen in 2012. Our count is a bit lower than the FDA’s count of 27 new approvals, because we did not include imaging agents like Navidea’s Lymphoseek, or reformulations like J&J’s Simponi Aria. 2013 was the first year the breakthrough-designated therapies were approved, with three breakthrough therapies approved: Gilead’s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Submits Comments to the EPA’s 2014 RVO Proposed Rule

Gas-Can-Spilling-Corn-115x76

The public comment period for the Environmental Protection Agency’s (EPA) 2014 proposal on the Renewable Volume Obligations (RVO) closed Tuesday January 28, 2014, with the agency receiving 16,575 comments.  On behalf of its members, BIO submitted over fifty pages of comments, stressing that the proposed changes to the RFS would be detrimental to the cellulosic and advanced biofuels industry. In a recent press release, Brent Erickson, executive vice president of BIO’s Industrial & Environmental Section, stated Read More >

Environmental & Industrial  |  Leave a comment  |  Email This Post
Tags: , , , ,

IPAB: Bad Medicine for Patient Care

DC in Fall

The Independent Payment Advisory Board is bad medicine for patient care, deficit reduction and containing Medicare costs. This board, consisting of 15 bureaucrats appointed by the President, has been given the power to make decisions affecting patients’ quality of care, with almost no oversight and no means for challenging its decisions. IPAB must be repealed. There is widespread support among patient advocacy groups and members of Congress on both sides of the aisle for full Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,